Glaukos (NYSE:GKOS) COO Joseph Gilliam Sells 60,000 Shares

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 60,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the sale, the chief operating officer owned 72,588 shares in the company, valued at approximately $13,046,967.12. The trade was a 45.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $189.09 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $189.69. The company has a market capitalization of $11.15 billion, a P/E ratio of -58.18 and a beta of 0.78. The firm’s 50 day simple moving average is $150.03 and its two-hundred day simple moving average is $128.97.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) earnings per share. Research analysts expect that Glaukos Corporation will post -0.35 EPS for the current fiscal year.

Institutional Trading of Glaukos

Several hedge funds have recently bought and sold shares of GKOS. Wealth Alliance LLC grew its position in shares of Glaukos by 4.5% during the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock valued at $247,000 after purchasing an additional 98 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Glaukos by 9.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $158,000 after buying an additional 122 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 132 shares in the last quarter. CWM LLC boosted its stake in Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 143 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in Glaukos by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after buying an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on GKOS. Truist Financial raised their price target on Glaukos from $180.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Stifel Nicolaus increased their target price on Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. William Blair reissued an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Finally, HC Wainwright lifted their target price on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $177.33.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.